Edit
Merus Labs International Inc.
http://www.meruslabs.com/Last activity: 30.04.2015
Active - Reference to Norgine
Merus Labs International Inc. is a specialty pharmaceutical company engaged in the acquisition and licensing of niche pharmaceutical products throughout North America. By capitalizing on its expertise of the North American pharmaceutical markets and access to capital, Merus is currently focused on building its portfolio of products. Merus strategically develops the sale and distribution of their product line by introducing a targeted re-launch marketing and promotional plan. PowerOne was instrumental in the creation of the company and has helped Merus raise over $100M in Debt and Equity since its inception.
Visit Website
Visit Website
Investors 1
| Date | Name | Website |
| - | PowerOne C... | poweroneca... |
Mentions in press and media 6
| Date | Title | Description |
| 30.04.2015 | Merus Labs closes $60-million bought-deal financing | April 30, 2015 |
| 10.06.2013 | Merus Announces Closing of Private Placement | June 10, 2013 |
| 07.03.2012 | CRTX sells rights to two drugs, shifts focus to drugs sold in hospitals | The deals also include Cornerstone’s oral antibiotic Spectracef, but no details on that transaction were disclosed. The Spectracef family of products generated $8 million in 2011 sales. For Cornerstone, the deals are consistent with a strat... |
| 14.10.2011 | Merus Labs International Inc. announces proceeds of the warrant incentive program and repayment of short term credit facility | VANCOUVER, Oct. 14, 2011 /CNW/ – Merus Labs International Inc. (the “Company”) is pleased to announce that 16,324,250 warrants were exercised pursuant to the warrant incentive program (the “Program”) announced by the Company on September 28... |
| 23.03.2011 | Merus Labs International Inc. Announces Closing Of Non-Brokered Private Placement | March 23, 2011 |
| - | CRTX sells rights to two drugs, shifts focus to drugs sold in hospitals | Cornerstone Therapeutics (NASDAQ:CRTX) has sold rights to two anti-infective products in deals that complete the specialty pharmaceutical company’s shift away from marketing primary care drugs. Cornerstone will now focus on marketing hospit... |